CRISPR Therapeutics (CRSP) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Portfolio and pipeline
Portfolio spans CASGEVY, later-stage CTX310, zugo-cel and CTX611, plus earlier programs including A1AT, CTX340, type 1 diabetes, in vivo CAR T and in vivo HSC editing.
CTX310, zugo-cel and CTX611 could enter late-stage trials within about a year; the 2027 outlook includes continued portfolio progression and potential early CTX340 and A1AT data.
CTX310
In severe hypertriglyceridemia, CTX310 showed a mean triglyceride reduction close to 65%; 8 of 10 patients were below 500 at day 28, a threshold associated with reducing pancreatitis risk.
LDL, ApoB and non-HDL cholesterol also declined, which was presented as a differentiation from APOC3 approaches; responses had deepened over time in early observations.
The one-time ANGPTL3 treatment produced durable lipid reductions through one year in earlier data; further data are expected on glucose control and hepatic fat in the coming year.
RMAT designations cover severe hypertriglyceridemia and LDL reduction; management aims to advance quickly toward late-stage trials, with an FDA RMAT meeting expected to help shape a potential Phase III design.
Severe hypertriglyceridemia is the initial development path; mixed dyslipidemia and homozygous familial hypercholesterolemia, including patients with inadequate PCSK9 response, are also potential trial settings.
Zugo-cel
Zugo-cel is an allogeneic CD19 CAR T with CRISPR edits intended to drive potent expansion while cells are cleared; management sees transient persistence as potentially advantageous for autoimmune disease.
In the scleroderma cohort, 6 of 7 patients had an early CRISS-25 response; the 2 patients beyond six months had CRISS-50 responses, with responses reported to deepen over time.
Three patients had interstitial lung disease at baseline; no continued decline was observed, and some rapidly progressing patients stabilized. Lung-function improvement may take beyond month six; an update could come in 2027.
Trials include lupus, myositis and scleroderma, with neuroimmune indications added; management plans to increase the dose after limited expansion in some patients and cited COGS below $10,000 per patient.
Latest events from CRISPR Therapeutics
- CASGEVY growth and pipeline advances alongside $2,276.6m in liquidity.CRSP
Q3 2026 - CASGEVY and three late-stage assets drive growth, with pivotal data and global expansion ahead.CRSP
Morgan Stanley 24th Annual Global Healthcare Conference - CRISPR-Cas9 editing of ANGPTL3 achieved sustained lipid reductions with favorable safety at 1 year.CRSP
Corporate presentation - Revenue and liquidity surged in Q2 2026, with major clinical and regulatory milestones achieved.CRSP
Q2 2026 - Broad CRISPR pipeline advances with commercial traction and key data readouts expected within a year.CRSP
Guggenheim Securities Inaugural Healthcare Innovation Conference - Strategic partnerships and advancing pipeline set up multiple near-term value catalysts.CRSP
H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 - Pipeline advances and financial strength drive growth, with profitability targeted by 2028.CRSP
Guggenheim Securities 2nd Annual Healthcare Innovation Conference - Gene editing and CAR-T breakthroughs drive clinical and commercial momentum into 2026.CRSP
44th Annual J.P. Morgan Healthcare Conference - 2025 poised for major value creation with global launches, pivotal data, and pipeline expansion.CRSP
43rd Annual J.P. Morgan Healthcare Conference 2025